These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 22208025)

  • 1. [LH-RH analogue].
    Ogawa Y; Igarashi A
    Nihon Rinsho; 2011 Jun; 69 Suppl 5():469-72. PubMed ID: 22208025
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of receptors for luteinizing hormone-releasing hormone (LH-RH) in prostate cancers following therapy with LH-RH agonists.
    Liu SV; Schally AV; Hawes D; Xiong S; Fazli L; Gleave M; Cai J; Groshen S; Brands F; Engel J; Pinski J
    Clin Cancer Res; 2010 Sep; 16(18):4675-80. PubMed ID: 20670943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical evaluation of targeted cytotoxic luteinizing hormone-releasing hormone analogue AN-152 in androgen-sensitive and insensitive prostate cancers.
    Letsch M; Schally AV; Szepeshazi K; Halmos G; Nagy A
    Clin Cancer Res; 2003 Oct; 9(12):4505-13. PubMed ID: 14555524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Assessment of the quality of life (QOL) of prostatic cancer patients under LH-RH analogue treatment].
    Ueda S; Nishi K; Yoshida M
    Nihon Rinsho; 1998 Aug; 56(8):2119-23. PubMed ID: 9750519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study on prevention of flare-up phenomenon following initial LH-RH analogue administration: combination therapy with diethylstilbestrol].
    Takeuchi S; Yoshida K; Tosaka A; Kobayashi N; Higashi Y; Negishi T
    Hinyokika Kiyo; 1995 Mar; 41(3):191-6. PubMed ID: 7741071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of prostatic cancer by LH-RH agonist.
    Imai K; Yamanaka H; Yuasa H; Yoshida M; Asano M; Kaetsu I
    Prog Clin Biol Res; 1987; 243A():429-34. PubMed ID: 3116552
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the chronic administration of LH-RH agonist on the oral glucose tolerance test in patients with prostatic carcinoma.
    González-Bárcena D; Pérez-Sánchez P; Hernández-Meza AR; Rangel-García N; Graef-Sánchez A; Comaru-Schally AM; Schally AV
    Arch Invest Med (Mex); 1987; 18(4):273-8. PubMed ID: 2969222
    [No Abstract]   [Full Text] [Related]  

  • 9. [History of clinical studies on hypothalamic hormone analogs in Mexico].
    Schally AV; González Bárcena D
    Gac Med Mex; 2006; 142(4):315-25. PubMed ID: 17022307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A comparison of the quality of life of prostatic cancer patients under slow releasing LH-RH analogue (TAP-144SR Depot) treatment or synthetic estrogen treatment].
    Oishi K; Arai Y; Takeuchi H; Yoshida O
    Hinyokika Kiyo; 1991 Sep; 37(9):1017-22. PubMed ID: 1785408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research and development of leuplin, a highly potent LH-RH analogue].
    Fujino M
    Tanpakushitsu Kakusan Koso; 2000 Apr; 45(6 Suppl):1114-8. PubMed ID: 10771682
    [No Abstract]   [Full Text] [Related]  

  • 12. Uncommon course of carcinoma of the prostate after radical prostatectomy and luteinizing hormone-releasing hormone analogue therapy.
    Pauer W; Eckerstorfer GM
    J Urol; 1998 Oct; 160(4):1432-3. PubMed ID: 9751377
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prostatic cancer. Treatment with LH-RH analogs].
    Ogreid P
    Tidsskr Nor Laegeforen; 1986 Dec; 106(34-36):2968-70. PubMed ID: 3544333
    [No Abstract]   [Full Text] [Related]  

  • 14. [The LH-RH analogs. Drug treatment of prostate cancer].
    Gerson C
    Soins; 1995 Nov; (600):61-2. PubMed ID: 8715119
    [No Abstract]   [Full Text] [Related]  

  • 15. Luteinizing hormone-releasing hormone analogues and hormone ablation for prostate cancer: state of the art.
    Schally AV
    BJU Int; 2007 Jul; 100 Suppl 2():2-4. PubMed ID: 17594347
    [No Abstract]   [Full Text] [Related]  

  • 16. [LH-RH derivative].
    Miyake H; Fujisawa M
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():313-6. PubMed ID: 25831774
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment of prostatic cancer with slow-release formulation of luteinizing hormone releasing hormone (LH-RH) analog].
    Fuse H; Akimoto S; Akakura K; Shimazaki J; Murakami S
    Hinyokika Kiyo; 1988 Mar; 34(3):555-60. PubMed ID: 3133936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of the initial testosterone surge induced by a luteinizing hormone-releasing hormone analogue in prostate cancer patients: the endocrinological effects of pretreatment with chlormadinone acetate.
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    J Med Invest; 1999 Feb; 46(1-2):55-8. PubMed ID: 10408158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The use of agonist analogues of luteinizing hormone--releasing hormone in the treatment of prostatic carcinoma].
    Gez E; Ben-Yosef R; Libson E; Biran S
    Harefuah; 1987 Mar; 112(5):239-41. PubMed ID: 3301586
    [No Abstract]   [Full Text] [Related]  

  • 20. [Luteinizing hormone-releasing hormone agonists for treatment of prostatic cancer].
    Gez E
    Harefuah; 1990 Apr; 118(8):483-6. PubMed ID: 2192959
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.